A bioequivalence study of Levothyroxine tablets versus an oral Levothyroxine solution in healthy volunteers

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 31, Issue 2, 2006, Pages 73-78

  Yannovits, N ^a   Zintzaras, E ^b   Pouli, A ^a   Koukoulis, G ^b   Lyberi, S ^c   Savari, E ^c   Potamianos, S ^b   Triposkiadis, F ^b   Stefanidis, I ^b   Zartaloudis, E ^d   Benakis, A ^e  

^a SKYLAB   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c Sismanogllon General Hosptial of Athens   (Greece)

^d NI THE Ltd   (Greece)

^e UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Bioequivalence study; Healthy volunteer; Levothyroxine; T3; Thyrohormone ; TSH

Indexed keywords

LEVOTHYROXINE; LEVOTHYROXINE SODIUM; LIOTHYRONINE; PROTIRELIN; THYROHORMONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CAUCASIAN; CHEMOLUMINESCENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; ELECTROIMMUNOASSAY; FEMALE; FOOD AND DRUG ADMINISTRATION; HEPARINIZATION; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NORMAL HUMAN; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION; TREATMENT FAILURE;

EID: 33746662331     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191122     Document Type: Article

References (27)

1. Taurog A. (2000): Hormone synthesis: thyroid hormone metabolism. In: The Thyroid: Fundamental and Clinical Text, 8th ed, Braverman L.E., Utiger R.D. (eds), Lippincott Williams and Wilkins, Philadelphia. p. 61.
2. Klein I, Ojama K. (2001): Thyroid hormone and the cardiovascular system. N. Engl. J. Med., 344, 501-509.
3. Leonard JL, Koehrle J. (2000): Intracellular pathways of iodothyronine metabolism. In: The Thyroid: Fundamental and Clinical Text, 8th ed, Braverman L.E., Utiger R.D. (eds), Lippincott Williams and Wilkins, Philadelphia. p. 136.
4. Anderson G.W., Mariash C.N., Oppenheimer J.H. (2000): Molecular actions of thyroid hormone. In: The Thyroid: Fundamental and Clinical Text, 8th ed, Braverman L.E., Utiger R.D. (eds), Lippincott Williams and Wilkins, Philadelphia. pp. 174-195.
5. Nakabayashi K., Matsumi H., Bhalla A., Bae J., Mosselman S., Hsu S.Y., Hsueh A.J. (2002): Thyrostimulin, a heterodimer of two new human glycoprotein hormone subunits, activates the thyroid-stimulating hormone receptor. J. Clin. Invest., 109, 1445-1452.
6. Shupnik M.A., Ridgway B.C., Chin W.W. (1989): Molecular biology of thyrotropin. Endocr. Rev., 10, 459-475.
7. Dyess E.M., Segerson T.P., Liposits Z., Paull W.K., Kaplan M.M., Wu P., Jackson I.M., Lechan R.M. (1988): Triiodothyronine exerts direct cell-specific regulation of thyrotropin-releasing hormone gene expression in the hypothalamic paraventricular nucleus. Endocrinology, 123, 2291-2297.
8. Engler D., Burger A.G. (1984): The deiodination of the iodothyronines and of their derivatives in man. Endocr. Rev., 5, 151-184.
9. Pauletzki J., Stellaard F., Paumgartner G. (1989): Bile acid metabolism in human hyperthyroidism. Hepatology, 9, 852-855.
10. Wiersinga W.M. (2001): Thyroid hormone replacement therapy. Horm. Res., 56(Suppl 1), 74-81.
11. Helfand M., Crapo L.M. (1990): Monitoring therapy in patients taking levothyroxine. Ann. Intern. Med., 113, 450-454.
12. Carr D., McLeod D.T., Parry G., Thornes H.M. (1988): Fine adjustment of thyroxine replacement dosage: comparison of the thyrotropin releasing hormone test using a sensitive thyrotropin assay with measurement of free thyroid hormones and clinical assessment. Clin. Endocrinol. (Oxf), 28, 325-333.
13. Canaris G.J., Manowitz N.R., Mayor G., Ridgway B.C. (2000): The Colorado thyroid disease prevalence study. Arch. Intern. Med., 160, 526-534.
14. Hollowell J.G., Staehling N.W., Flanders W.D., Hannon W.H., Gunter E. W., Spencer C.A., Braverman L.E. (2002): Serum TSH, T4, and thyroid antibodies in the United States Population (1988 to 1994): National Health and Nutritional Examination Survey (NHANES III). J. Clin. Endocrinol. Metab., 87, 489-499.
15. Sanchez-Carbayo M., Mauri M., Alfayate R., Miralles C., Soria F. (1999): Analytical and clinical evaluation of TSH and thyroid hormones by electrochemiluminescent immunoassays. Clin. Biochem., 32, 395-403.
16. Zintzaras E., Bouka P. (1999): Bioequivalence studies: biometrical concepts of alternative designs and pooled analysis. Eur. J. Drug Metab. Pharmacokinet., 24, 225-232.
17. Zintzaras E., Bouka P., Kowald A. (2002) Biometrical evaluation of bioequivalence trials using a bootstrap individual direct curve comparison method. Eur. J. Drug Metab. Pharmacokinet., 27, 11-16.
18. Zintzaras E. (2005) Statistical aspects of bioequivalence testing between two medicinal products. Eur. J. Drug Metab. Pharmacokinet., 30, 41-46.
19. Fountoulaki K., Dimopoulos V., Giannakoulis J., Zintzaras E., Triposkiadis F. (2005): Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartan. Am. J. Hypertens., 18, 171-177.
20. Zintzaras E. (2000): The existence of sequence effect in cross-over bioequivalence trials. Eur. J. Drug Metab. Pharmacokinet., 25, 241-244.
21. Zintzaras E. (1992) Statistical assessment of the synergistic effect between a vaccine and a drug. J. Pharm. Pharmacol., 44, 873-874.
22. Hauschke D., Steinjans V.W., Diletti E. (1990): A distribution-free procedure for the statistical analysis of bioequivalence studies. Int. J. Clin. Pharmacol. Ther. Toxicol., 28, 72-78.
23. Schuirmann D.J. (1987): A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm., 6, 657-680.
24. CPMP/EWP/QWP/1401/98, Note for Guidance on the Investigation of Bioavailability and Bioequivalence, adopted July 2001 (http://www.emea.eu.int/ pdfs/human/ewp/140198en.pdf).
25. Murray G.M. (1891): Note on the treatment of myxedema by hypodermic injections of an extract of the thyroid gland of a sheep. Br. Med. J., 2, 796-797.
26. Keating F.R. Jr., Parkin T.W., Selby J.B., Dickinson L.S. (1961): Treatment of heart disease associated with myxedema. Prog. Cardiovasc. Dis., 3, 364-381.
27. Benvenga S., Bartolone L., Squadrito S., Lo Giudice F., Trimarchi F. (1995): Delayed intestinal absorption of levothyroxine. Thyroid, 5, 249-253.